论文部分内容阅读
Crizotinib(商品名XALKORI)是1种酪氨酸激酶受体抑制剂,于2011年8月由美国FDA批准用于治疗FDA批准的检测方法确认为间变性淋巴瘤酶激酶(ALK)阳性的晚期或转移性的非小细胞肺癌(NSCLC)。Crizotinib的化学名为
Crizotinib (trade name XALKORI), a tyrosine kinase receptor inhibitor, was approved by the FDA in August 2011 to treat FDA-approved tests as an anaplastic lymphoma kinase (ALK) -positive late or Metastatic non-small cell lung cancer (NSCLC). The chemical name of Crizotinib is